The Medicines and Healthcare Products Regulatory Agency (MHRA) has released its 2020-21 business plan, outlining its primary goals for the coming year. Driven by the need to develop new regulatory models and improving patient access to cutting-edge drugs and medical devices, the plan concerns various aspects of the British life sciences industry, including the efficacy and efficiency of clinical trial supplies. In the executive summary, the plan sets out the primary aim of “driving forward a substantial strategic and cultural change through 2020-21”. Though the document discusses a range of granular challenges in healthcare and medicine, two of the biggest issues covered are the
Matrix Healthcare Solutions further expands licensed capabilities with the addition of Manufacturer’s “Specials” (MS) license.
Various news outlets around the world have reported on apparent clinical trials testing the efficacy of anti-HIV (human immunodeficiency viruses) medication in combatting COVID-19.
Zac has focused his career in the pharmaceutical industry, sourcing comparative medicines for use in a wide category of Clinical Trials.
Alongside several key brick-and-mortar expansions, Matrix Healthcare Solutions (MHS) has also developed a wider base of licensed capabilities, allowing us to support a broader range of customer requirements.
Matrix Healthcare Solutions are delighted to welcome Will Plumb into the team as Director, Clinical Supplies.
Matrix Healthcare Solutions (MHS) has recently expanded by opening a dedicated divisional headquarters in Tokyo, Japan; the epicentre of Asia-Pacific’s growing pharmaceutical industry.
Matrix Healthcare Solutions (MHS) opens global headquarters at Alderly Park, as part of a concerted effort to expand and improve our global business model.